Tata Elxsi has unveiled AnaTel™, an innovative AI-native software development platform tailored for the healthcare and medical technology sectors, in collaboration with OpenAna.
Launched at DeviceTalks Boston 2026, AnaTel™ aims to tackle increasing operational challenges faced by medtech software teams, particularly in light of stringent regulatory requirements for AI-enabled device software. With the FDA and European guidelines demanding rigorous lifecycle documentation and validation, AnaTel™ integrates autonomous AI agents into the engineering workflow to streamline compliance processes.
This platform supports the entire AI-Driven Software Delivery Lifecycle, from initial requirements to deployment and ongoing optimization. By generating necessary documentation and regulatory artifacts, AnaTel™ significantly enhances productivity and reduces development timelines for Software as a Medical Device (SaMD) from eight weeks to just 72 hours. It ensures that human engineers and regulatory experts maintain control at all critical decision points, aligning with eSTAR submission requirements.
The development of AnaTel™ leverages Tata Elxsi’s deep expertise in regulated medical environments, positioning it as a robust solution for navigating the complexities of compliance and traceability in medtech. This partnership with OpenAna emphasizes the importance of combining autonomous AI capabilities with human oversight in the demanding healthcare sector, ultimately aiming to accelerate the delivery of regulatory-ready software.